Compare the Pharmacokinetics of NVP-1205 and Coadministration of Rosuvastatin and Ezetimibe (NVP-1205)

March 24, 2016 updated by: NVP Healthcare

A Clinical Trial to Compare the Pharmacokinetics and Safety of NVP-1205 and Coadministration of Rosuvastatin and Ezetimibe in Healthy Male Volunteers

The purpose of this study is to compare the pharmacokinetics of NVP-1205 and coadministration of rosuvastatin and ezetimibe.

Study Overview

Status

Completed

Conditions

Detailed Description

rosuvastatin and ezetimibe(anti-dyslipidemia)

Study Type

Interventional

Enrollment (Actual)

41

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Daegu
      • Jung-gu, Daegu, Korea, Republic of, 700-721
        • Kyungpook National Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

19 years to 55 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Healthy male subjects age between 19 and 55 signed informed consent

Exclusion Criteria:

  • subjects have a history of allergy reaction of this drug or other drugs

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Screening
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: NVP-1205
administration of NVP-1205(rosuvastatin+ezetimibe)
rosuvastatin/ezetimibe fixed dose combination orally, once daily on Period 1 or Period 2
Other Names:
  • NVP-1205(rosuvastatin+ezetimibe)
Active Comparator: rosuvastatin and ezetimibe
coadministration of rosuvastatin and ezetimibe
coadministration of rosuvastatin and ezetimibe orally, once daily on Period 1 or Period 2
Other Names:
  • Crestor and Ezetrol

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
AUClast
Time Frame: 0-96hr
0-96hr

Secondary Outcome Measures

Outcome Measure
Time Frame
AUCinf
Time Frame: 0-96hr
0-96hr

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Yoon Yo Ran, M.D., Ph,D., Kyungpook National University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2014

Primary Completion (Actual)

March 1, 2014

Study Completion (Actual)

March 1, 2014

Study Registration Dates

First Submitted

January 5, 2014

First Submitted That Met QC Criteria

January 6, 2014

First Posted (Estimate)

January 8, 2014

Study Record Updates

Last Update Posted (Estimate)

March 25, 2016

Last Update Submitted That Met QC Criteria

March 24, 2016

Last Verified

March 1, 2016

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Dyslipidemia

Clinical Trials on NVP-1205

3
Subscribe